SYGNIS AG Signs Distribution Agreement with Mayflower Bioscience
News Dec 03, 2015
SYGNIS AG has announced that it has signed a distribution agreement with Mayflower Bioscience LLC (St. Louis, USA) for the commercialization of SYGNIS’ proprietary product portfolio in the USA.
Under the terms of the agreement, SYGNIS has granted Mayflower Bioscience the rights to promote, market and sell all existing as well as future product lines to scientists working in genomics, proteomics and diagnostics in the USA.
These product lines cover the Company’s revolutionary TruePrime™ products for primer-free whole genome amplification (WGA) as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA including the newly launched SunScript™ One Step Reverse Transcriptase (RT)-PCR Kit for parallel transcription and amplification of genomic information.
Mayflower Bioscience is a distributor of unique life science research products, providing their customers with the latest innovations for biological research, drug discovery and bioproduction, with an emphasis on solutions for cell biology, molecular biology and drug discovery.
“The distribution agreement with Mayflower represents the next logical and consistent step in SYGNIS’ strategy. After having successfully built an extensive distribution network covering the most important life science markets in Europe and Asia, we are now entering the USA, the biggest and fastest growing life science market worldwide,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “Mayflower is a specialist provider particularly for high level research centers focused on Next Generation Sequencing (NGS). The NGS market in the USA represents more than 50% of the global market. Mayflower provides a broad US customer data base and deep knowledge of the customers needs, and is ideally suited to market and commercialize our existing and future product portfolio.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE